In pediatric cannabinoid hyperemesis syndrome, nontraditional antiemetics (benzodiazepines, haloperidol, capsaicin) appeared more effective than traditional antiemetics at resolving symptoms.
Read this if you are a clinician treating adolescents with CHS or a parent of a teen with cannabis-related vomiting.
Nontraditional > traditionalBenzodiazepines, haloperidol, capsaicin more effective than standard antiemetics for pediatric CHS
What the researchers found
In a retrospective review of pediatric CHS patients at Penn State Children's Hospital, nontraditional antiemetic medications (benzodiazepines, haloperidol, topical capsaicin) appeared more effective in resolving symptoms compared to traditional antiemetics (ondansetron, etc.). Analysis of all ordered antiemetics demonstrated a gap in symptom resolution between nontraditional and traditional agents. Adverse effects were minimal for both categories. Cannabis abstinence remains the most effective approach.
Why it matters
CHS in adolescents is increasing with cannabis legalization. Standard anti-nausea medications often fail, leading to repeated ER visits. This study provides evidence-based guidance for selecting more effective treatments in the pediatric population.
The numbers in context
- Retrospective review of pediatric CHS cases
- Age ≤18 years
- Nontraditional agents: more effective for symptom resolution
- Traditional agents: less effective
- Minimal adverse effects in both categories
- Abstinence remains most effective overall approach
How the study worked
Retrospective review of electronic health records at Penn State Children's Hospital. Patients ≤18 with CHS-related diagnosis codes meeting diagnostic criteria. Efficacy assessed via subjective nausea reports and objective vomiting documentation.
Who was studied
Pediatric and adolescent patients (≤18 years) with cannabinoid hyperemesis syndrome
What this study cannot tell us
Retrospective single-center study. Small sample size (specific numbers not in abstract). Selection bias in medication choice. CHS diagnosis may be inconsistent across providers.
How to read the evidence
Retrospective single-center case series. Provides initial comparative data but limited by design and sample size.
When this study was published
Published in 2023. Among the first studies to compare antiemetic approaches specifically in pediatric CHS.
The bigger picture
The recognition that CHS requires different treatment from standard vomiting syndromes is relatively new. Traditional antiemetics that work for other causes of nausea are often ineffective for CHS, and this pediatric data aligns with adult CHS treatment literature.
Questions still open
- What is the optimal first-line nontraditional antiemetic for pediatric CHS?
- Could droperidol be a better option than haloperidol for pediatric patients?
- Would outpatient topical capsaicin reduce ER visits for CHS?
Read the original research
Comparison of Antiemetics in the Management of Pediatric Cannabinoid Hyperemesis Syndrome.
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 28(3), 222-227
Citation
Geraci, Emily; Cake, Carrie; Mulieri, Kevin M; Fenn, Norman E. (2023). Comparison of Antiemetics in the Management of Pediatric Cannabinoid Hyperemesis Syndrome.. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 28(3), 222-227. https://doi.org/10.5863/1551-6776-28.3.222